Paying For Personalized Medicine: Medicare CED Approach Proposed
This article was originally published in The Pink Sheet Daily
Executive Summary
Any CMS national coverage determination on diagnostics used to tailor drug therapy should consider coverage with evidence development - Personalized Medicine Coalition.
You may also be interested in...
Is CMS Coverage Of Warfarin Dosing Tests Supported By Data? Opinions vary
Comments on coverage of genomic testing closed Sept. 4; CMS expects to issue a proposal memo by Feb. 4, complete its national coverage analysis by May 5, 2009.
As Amgen Drops Some ESA “Overhangs,” New Payment Threat Appears
Amgen could be facing a new threat on the reimbursement front just days after celebrating the removal of several "major overhangs" to its erythropoiesis-stimulating agents during its second quarter earnings call
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.